Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 2/20 | 0.54 |
| ▸ | DRD1 | P21728 | 1/20 | 0.54 |
| ▸ | DRD5 | P21918 | 1/20 | 0.54 |
| ▸ | DRD3 | P35462 | 1/20 | 0.54 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.49 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.49 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.49 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.43 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.43 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24702156 | 0.89 | DRD2 (0.55) | DRD2DRD1DRD5DRD3GABRA1 | |
| SCHEMBL16624022 | 0.88 | ABHD6 (0.50) | DRD2DRD1DRD5DRD3GABRA1 | |
| SCHEMBL27010070 | 0.85 | ABHD6 (0.47) | DRD2DRD1DRD5DRD3GABRA1 | |
| SCHEMBL19708231 | 0.79 | HRH3 (0.43) | DRD2 | |
| SCHEMBL5568684 | 0.79 | DRD1 (0.77) | DRD2DRD1DRD5DRD3 | |
| SCHEMBL23102140 | 0.78 | ADRA2A (0.57) | DRD2 | |
| SCHEMBL24316260 | 0.78 | KCNH2 (0.48) | DRD2DRD3 | |
| SCHEMBL10199308 | 0.78 | HRH3 (0.39) | DRD2DRD1DRD5DRD3GABRA1 | |
| SCHEMBL23509326 | 0.78 | CD44 (0.44) | — | |
| SCHEMBL24317348 | 0.78 | DRD2 (0.56) | DRD2DRD1DRD5DRD3CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240018118-A1 | TRICYCLIC COMPOUNDS TO DEGRADE NEOSUBSTRATES FOR MEDICAL THERAPY | C 4 Therapeutics, Inc. (US) | 2024-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240018118-A1 | TRICYCLIC COMPOUNDS TO DEGRADE NEOSUBSTRATES FOR MEDICAL THERAPY | NFATC1, CTSS, MMP12 | DRD2 4598/4885DRD1 4246/4885DRD5 4596/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.